Physician profile
Lilly Bontrager
NPI 1033120993
$1,470.18
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,323 · 2020: $148.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $252.28 | 2019-2020 | |
| Novo Nordisk INC | $181.29 | 2019-2020 | |
| Glaxosmithkline, LLC. | $166.18 | 2019-2020 | |
| Lilly USA, LLC | $154.69 | 2019 | |
| Janssen Pharmaceuticals, INC | $133.86 | 2019 | |
| Merck Sharp & Dohme LLC | $108.52 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.95 | 2019-2020 | |
| Pfizer INC. | $57.46 | 2019-2020 | |
| Abbvie INC. | $49.59 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.41 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $35.81 | 2019 | |
| Radius Health, INC. | $32.48 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.99 | 2019 | |
| Sanofi-Aventis U.S. LLC | $28.63 | 2019 | |
| Grifols USA, LLC | $24.06 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $21.65 | 2019 | |
| Amarin Pharma, INC. | $15.26 | 2019 | |
| Amgen INC. | $14.79 | 2019 | |
| Tris Pharma INC | $14.48 | 2019 | |
| Allergan, INC. | $11.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lilly Bontrager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.